Project Grant 2451628
Award Date
4/1/25
Completion Date
3/31/26
Dollars Obligated
$304K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Ladera Ranch, CA, USA
Similar Awards
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Om Therapeutics Inc. to develop innovative technology for the high-throughput screening of small molecule and protein interactions. The project aims to enable the rapid and cost-effective discovery of new medicines by encapsulating proteins and small molecules in millions of barcoded micro-compartments to identify specific...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and...
This SBIR Phase I Project Grant award of $275,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a high-throughput platform for small molecule, in-cell targeting of undruggable proteins via their messenger RNAs (mRNAs). The project will address the unmet need of targeting mRNAs directly with small molecule drugs to treat hard-to-treat diseases, including neurodegenerative diseases and aggressive cancers, which...
The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $294,947 to Percept Biosciences Inc. located in San Diego, CA. The funding will support the development of a software tool to automate the creation of drug repurposing development plans. The tool aims to accelerate the drug repurposing process by integrating relevant data sources, optimizing drug targets and candidates, and generating...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,550 to Biocognon LLC provides funding to develop a novel yeast-based high-throughput screening platform for efficiently generating molecular recognition domains that can specifically recognize clinically important targets. The goal is to integrate breakthroughs in next-generation DNA sequencing, synthetic biology, and computational biology to create a combinatorial...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $275,000 to Altay Therapeutics, Inc., a biotechnology company, to develop novel small molecule therapies that target disease-causing transcription factors for treating chronic illnesses and cancers. The key goals of this SBIR Phase I project are to: (1) determine the toxicity profile of new inhibitors across human cells, (2) measure drug specificity to the target...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Ubiquitx Inc., a New York-based small business, to develop a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs) using artificial intelligence, protein engineering, and mRNA therapeutics. The goal is to expand the applications of the company's Chimeric Ligands for Induced Proximity (CLIPS)...
This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve...